ABCG2 and cancer: Another ruthenium compound(RuF, Scheme 1B) wasdeveloped by Zeng et al. as a BCRP inhibitor.5 In this work, the authors showed that RuF was able to overcome mitoxantroneresistance in lung H460/MX20 cancer cells by downregulating BCRP expressionand by inhibiting BCRP ATPase activity.